不同剂量人脐带间充质干细胞移植治疗MS效果观察

发布时间：2018-03-29 14:13

  本文选题：多发性硬化　切入点：人脐带血间充质干细胞　出处：《山东医药》2017年37期

【摘要】：目的对比观察不同剂量人脐带间充质干细胞(hUC-MSC)移植治疗多发性硬化(MS)的临床效果。方法将60例MS患者随机均分为A、B、C、D组。从足月健康新生儿脐带中提取hUC-MSC;各组均采用BEAM方案(卡莫司汀、替尼泊苷、阿糖胞苷、美法仑)进行预处理。A、B、C组采用腰椎穿刺术经蛛网膜下腔分别注射hUCMSC 1.5×10~6/kg、7.5×10~6/kg、15×10~6/kg,D组给予相同体积生理盐水。每2周移植1次,共移植3次。治疗前后采用扩展致残状况评分量表(EDSS)对患者神经功能缺损程度进行评分,采用MR检查头颅、脊髓病灶数量及病灶体积变化,统计患者治疗期间发生的不良反应。结果与治疗前比较,治疗后A、B、C组EDSS较D组低(P均0.05),且C组B组A组,两两比较差异有统计学意义(P均0.05)。治疗后A、B、C组病灶数目及体积均较D组小(P均0.05),且C组B组A组,两两比较差异有统计学意义(P均0.05)。治疗过程中B、D组各出现1例低等发热,经对症处理后均于3 d内恢复正常。结论在常规抗炎治疗基础上加hUC-MSC移植治疗能改善MS患者的临床症状;且在≤15×106/kg范围内,移植剂量越高治疗效果越佳。
[Abstract]:Objective to observe the clinical effect of different doses of human umbilical cord mesenchymal stem cells (hUC-MSC) in the treatment of multiple sclerosis (MS). Using the BEAM scheme (Carmosine, Teniposide, cytarabine, mefalen) pretreatment. Group C received lumbar puncture via subarachnoid space injection of hUCMSC 1.5 脳 10 ~ 6 / kg ~ 7.5 脳 10 ~ (-6) 路kg ~ (-1) 路kg ~ (-1) 脳 10 ~ (-6)% 路kg ~ (-1) 路kg ~ (-1) 路kg ~ (-1) 路kg ~ (-1) / kg ~ (15 脳 10 ~ (6)) 路kg ~ (-1) 路kg ~ (-1) 路kg ~ (-1). Before and after treatment, the degree of neurological impairment was evaluated by EDSS, the number of head, spinal cord lesions and the volume of lesions were examined by Mr. Results compared with those before treatment, the EDSS of group A was lower than that of group D (P 0.05), and that of group C was lower than that of group B (P 0.05), and that of group B (group A) was higher than that of group C (P < 0.05). After treatment, the number and volume of lesions in group A were significantly lower than those in group D, and there were significant differences between group A and group C (P < 0.05). During the course of treatment, there was one case of low fever in group B and group D, and the difference was significant in group A (P < 0.05), and there was a significant difference between group A and group C (P < 0.05). Conclusion the clinical symptoms of MS patients can be improved by hUC-MSC transplantation on the basis of routine anti-inflammatory therapy, and in the range of 鈮，

本文编号：1681489